What are the major opportunities in the Sarclisa market? What are the strategies for the Sarclisa market?

For detailed insights on the major opportunities and strategies in the Sarclisa market, Read More

How does the Sarclisa market relate to the overall economy and other similar markets?

For detailed insights on Sarclisa's relation to the overall economy and other similar markets, Read More

What are the latest mergers and acquisitions in the Sarclisa industry?

For detailed insights on the mergers and acquisitions in the Sarclisa industry, Read More

What are the key dynamics influencing the Sarclisa market growth? SWOT analysis of the Sarclisa market.

For detailed insights on the key dynamics influencing the Sarclisa market growth and SWOT analysis of the Sarclisa industry, Read More

Item added to cart!

Published : December 2025

Pages :

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00 $3367.00

Purchase This Report Download Sample PDF

Purchase This Report

Sarclisa Global Market Report 2025

Name: Sarclisa Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Formulation (Injectable Solution, Lyophilized Powder for Injection), By Clinical Indication (Relapsed Or Refractory Multiple Myeloma, Newly Diagnosed Multiple Myeloma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies)

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

What Is Covered Under Sarclisa Market?

Sarclisa is a monoclonal antibody used in the treatment of certain cancers, specifically multiple myeloma, a type of blood cancer. It works by targeting and binding to a protein called CD38, which is found on the surface of multiple myeloma cells. By binding to CD38, sarclisa helps the immune system recognize and destroy these cancerous cells. It is typically used in combination with other cancer therapies to improve treatment outcomes.

The main types of sarclisa formulations are injectable solution and lyophilized powder for injection. Relapsed or refractory multiple myeloma is a stage of multiple myeloma where the disease returns after initial treatment or no longer responds to therapy. It is used for relapsed or refractory multiple myeloma and newly diagnosed multiple myeloma and is distributed through both hospital and retail pharmacies.

Sarclisa Market Size and growth rate 2025 to 2029: Graph

What Is The Sarclisa Market Size 2025 And Growth Rate?

The sarclisa market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to significant investments in oncology research, improvements in healthcare infrastructure, increasing aging population, government funding and reimbursement policies for cancer treatments, and expanding clinical trial programs.

What Is The Sarclisa Market Growth Forecast?

The sarclisa market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to growth of personalized medicine, shift toward immunotherapies, increasing prevalence of autoimmune diseases, growing focus on long-term remission, and awareness of hematological malignancies. Major trends in the forecast period include shift towards more targeted therapies, launch of biosimilars, advancements in molecular diagnostics, technological advancements in cancer diagnosis, and innovation in targeted cancer therapies.

Book your 30 minutes free consultation with our research experts

How Is The Sarclisa Market Segmented?

The sarclisa market covered in this report is segmented –

1) By Formulation: Injectable Solution; Lyophilized Powder for Injection

2) By Clinical Indication: Relapsed Or Refractory Multiple Myeloma; Newly Diagnosed Multiple Myeloma

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies

What Is Driving The Sarclisa Market? Rising Cancer Prevalence Drives Growth In The Sarclisa Market

The increasing prevalence of cancer is expected to propel the growth of the sarclisa market going forward. Cancer is a group of diseases characterized by uncontrolled cell growth and division, which can invade surrounding tissues and spread to other parts of the body, often forming tumors or metastases, and can affect various organs or systems. The increasing prevalence of cancer can be attributed to factors such as an aging population, lifestyle choices, environmental exposures, genetic predispositions, and improved detection methods leading to better diagnosis. Sarclisa is essential for treating cancer, particularly multiple myeloma, as it targets and eliminates cancerous plasma cells, bolstering the immune system's capacity to combat the disease and enhancing treatment effectiveness. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that 2022 saw approximately 20 million new cancer cases and 9.7 million cancer-related deaths globally. Lung cancer was the most prevalent, accounting for 2.5 million new cases (12.4% of the total), followed by female breast cancer with 2.3 million cases (11.6%) and colorectal cancer with 1.9 million cases (9.6%). By 2050, new cancer cases are projected to exceed 35 million, representing a 77% increase from 2022. Therefore, the increasing prevalence of cancer is driving the growth of the sarclisa market.

What Is Driving The Sarclisa Market? Growth Of The Geriatric Population To Drive Market

The growing geriatric population is expected to propel the growth of the sarclisa market going forward. The geriatric population refers to older adults, typically those aged 65 and above, who often experience distinct health, social, and economic challenges as they age. The geriatric population is rising due to factors such as longer life expectancy, advances in healthcare, and declining birth rates, which collectively contribute to an aging global population. Sarclisa is crucial for the geriatric population as it provides an effective treatment option for multiple myeloma, especially for older adults who may not qualify for intensive therapies such as autologous stem cell transplants. For instance, in October 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, it is anticipated that one in six people worldwide would be 60 years of age or older by 2030. By 2030, there will likely be 1.4 billion people over 60, up from 1 billion in 2020. By 2050, this group is predicted to have doubled in size from its current size to 2.1 billion. Therefore, the growing geriatric population will drive the growth of the sarclisa market.

Who Are The Major Players In The Global Sarclisa Market?

Major companies operating in the sarclisa market are Sanofi S.A.

What Are The Key Trends Of The Global Sarclisa Market? Regulatory Approvals Drive Growth In The Sarclisa Market For Newly Diagnosed Multiple Myeloma

The key trend in the sarclisa market is securing drug approvals from regulatory authorities to treat adult patients with newly diagnosed multiple myeloma. Drug approval involves the evaluation and authorization of a new drug for sale and use, ensuring its safety, efficacy, and quality through rigorous clinical trial data assessment. For instance, in September 2024, Sanofi SA, a France-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option for adult patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT). This approval follows the positive results of the IMROZ phase 3 study, which indicated that sarclisa, when combined with VRd, significantly reduced the risk of disease progression or death by 40% compared to VRd alone. This marks Sarclisa's third indication and underscores Sanofi's commitment to addressing a critical need in the treatment of multiple myeloma.

Need data on a specific region in this market?

Request Regional Data

Regional Analysis For The Global Sarclisa Market

North America was the largest region in the sarclisa market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sarclisa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sarclisa market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Sarclisa Market?

The sarclisa market consists of sales of chemotherapy agents, immunotherapy drugs, biosimilars, and diagnostic kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Sarclisa Industry?

The sarclisa market research report is one of a series of new reports from The Business Research Company that provides sarclisa market statistics, including sarclisa industry global market size, regional shares, competitors with a sarclisa market share, detailed sarclisa market segments, market trends and opportunities, and any further data you may need to thrive in the sarclisa industry. This sarclisa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Author : Abhilash Pyata

Sarclisa Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	Included ?
Revenue Forecast In 2034	Included ?
Growth Rate	Included ?
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The sarclisa market covered in this report is segmented – 1) By Formulation: Injectable Solution; Lyophilized Powder for Injection 2) By Clinical Indication: Relapsed Or Refractory Multiple Myeloma; Newly Diagnosed Multiple Myeloma 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Sanofi S.A.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Sarclisa Market Characteristics

3. Sarclisa Market Biologic Drug Characteristics

3.1. Molecule Type

3.2. Route Of Administration (ROA)

3.3. Mechanism Of Action (MOA)

3.4. Safety And Efficacy

4. Sarclisa Market Trends And Strategies

5. Sarclisa Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

6. Global Sarclisa Growth Analysis And Strategic Analysis Framework

6.1. Global Sarclisa PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

6.2. Analysis Of End Use Industries

6.3. Global Sarclisa Market Growth Rate Analysis

6.4. Global Sarclisa Historic Market Size and Growth, 2019 - 2024, Value ($ Million)

6.5. Global Sarclisa Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)

6.6. Global Sarclisa Total Addressable Market (TAM)

7. Global Sarclisa Pricing Analysis & Forecasts

8. Sarclisa Market Segmentation

8.1. Global Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Injectable Solution

Lyophilized Powder for Injection

8.2. Global Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Relapsed Or Refractory Multiple Myeloma

Newly Diagnosed Multiple Myeloma

8.3. Global Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Hospital Pharmacies

Retail Pharmacies

9. Global Sarclisa Epidemiology Of Clinical Indications

9.1. Drug Side Effects

9.2. Incidence And Prevalence of Clinical Indications

10. Sarclisa Market Regional And Country Analysis

10.1. Global Sarclisa Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

10.2. Global Sarclisa Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

11. Asia-Pacific Sarclisa Market

11.1. Asia-Pacific Sarclisa Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

11.3. Asia-Pacific Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

11.4. Asia-Pacific Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

12. China Sarclisa Market

12.1. China Sarclisa Market Overview

12.2. China Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

12.3. China Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

12.4. China Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

13. India Sarclisa Market

13.1. India Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

13.2. India Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

13.3. India Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

14. Japan Sarclisa Market

14.1. Japan Sarclisa Market Overview

14.2. Japan Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

14.3. Japan Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

14.4. Japan Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

15. Australia Sarclisa Market

15.1. Australia Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

15.2. Australia Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

15.3. Australia Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

16. South Korea Sarclisa Market

16.1. South Korea Sarclisa Market Overview

16.2. South Korea Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

16.3. South Korea Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

16.4. South Korea Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

17. Western Europe Sarclisa Market

17.1. Western Europe Sarclisa Market Overview

17.2. Western Europe Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

17.3. Western Europe Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

17.4. Western Europe Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

18. UK Sarclisa Market

18.1. UK Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

18.2. UK Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

18.3. UK Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

19. Germany Sarclisa Market

19.1. Germany Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

19.2. Germany Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

19.3. Germany Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

20. France Sarclisa Market

20.1. France Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

20.2. France Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

20.3. France Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

21. Eastern Europe Sarclisa Market

21.1. Eastern Europe Sarclisa Market Overview

21.2. Eastern Europe Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

21.3. Eastern Europe Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

21.4. Eastern Europe Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

22. North America Sarclisa Market

22.1. North America Sarclisa Market Overview

22.2. North America Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

22.3. North America Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

22.4. North America Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

23. USA Sarclisa Market

23.1. USA Sarclisa Market Overview

23.2. USA Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

23.3. USA Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

23.4. USA Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

24. Canada Sarclisa Market

24.1. Canada Sarclisa Market Overview

24.2. Canada Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

24.3. Canada Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

24.4. Canada Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

25. South America Sarclisa Market

25.1. South America Sarclisa Market Overview

25.2. South America Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

25.3. South America Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

25.4. South America Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

26. Middle East Sarclisa Market

26.1. Middle East Sarclisa Market Overview

26.2. Middle East Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

26.3. Middle East Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

26.4. Middle East Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

27. Africa Sarclisa Market

27.1. Africa Sarclisa Market Overview

27.2. Africa Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

27.3. Africa Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

27.4. Africa Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

28. Sarclisa Market Competitive Landscape And Company Profiles

28.1. Sarclisa Market Competitive Landscape

28.2. Sarclisa Market Company Profiles

28.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

29. Global Sarclisa Market Pipeline Analysis

29.1. High Level Clinic Trail Information

30. Global Sarclisa Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Sarclisa Market

32. Recent Developments In The Sarclisa Market

33. Sarclisa Market High Potential Countries, Segments and Strategies

33.1 Sarclisa Market In 2029 - Countries Offering Most New Opportunities

33.2 Sarclisa Market In 2029 - Segments Offering Most New Opportunities

33.3 Sarclisa Market In 2029 - Growth Strategies

33.3.1 Market Trend Based Strategies

33.3.2 Competitor Strategies

34. Appendix

34.1. Abbreviations

34.2. Currencies

34.3. Historic And Forecast Inflation Rates

34.4. Research Inquiries

34.5. The Business Research Company

34.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Million

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Million

Table 3: Global Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 4: Global Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 5: Global Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 6: Global Sarclisa Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 7: Global Sarclisa Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 8: Asia-Pacific, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 9: Asia-Pacific, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 10: Asia-Pacific, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 11: China, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 12: China, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 13: China, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 14: India, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 15: India, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 16: India, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 17: Japan, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 18: Japan, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 19: Japan, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 20: Australia, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 21: Australia, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 22: Australia, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 23: South Korea, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 24: South Korea, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 25: South Korea, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 26: Western Europe, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 27: Western Europe, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 28: Western Europe, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 29: UK, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 30: UK, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 31: UK, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 32: Germany, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 33: Germany, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 34: Germany, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 35: France, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 36: France, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 37: France, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 38: Eastern Europe, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 39: Eastern Europe, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 40: Eastern Europe, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 41: North America, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 42: North America, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 43: North America, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 44: USA, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 45: USA, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 46: USA, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 47: Canada, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 48: Canada, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 49: Canada, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 50: South America, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 51: South America, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 52: South America, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 53: Middle East, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 54: Middle East, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 55: Middle East, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 56: Africa, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 57: Africa, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 58: Africa, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 59: Sanofi S.A. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Million

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Million

Figure 3: Global Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 4: Global Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 5: Global Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 6: Global Sarclisa Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 7: Global Sarclisa Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 8: Asia-Pacific, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 9: Asia-Pacific, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 10: Asia-Pacific, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 11: China, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 12: China, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 13: China, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 14: India, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 15: India, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 16: India, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 17: Japan, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 18: Japan, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 19: Japan, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 20: Australia, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 21: Australia, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 22: Australia, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 23: South Korea, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 24: South Korea, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 25: South Korea, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 26: Western Europe, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 27: Western Europe, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 28: Western Europe, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 29: UK, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 30: UK, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 31: UK, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 32: Germany, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 33: Germany, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 34: Germany, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 35: France, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 36: France, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 37: France, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 38: Eastern Europe, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 39: Eastern Europe, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 40: Eastern Europe, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 41: North America, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 42: North America, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 43: North America, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 44: USA, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 45: USA, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 46: USA, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 47: Canada, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 48: Canada, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 49: Canada, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 50: South America, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 51: South America, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 52: South America, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 53: Middle East, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 54: Middle East, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 55: Middle East, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 56: Africa, Sarclisa Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 57: Africa, Sarclisa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 58: Africa, Sarclisa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 59: Sanofi S.A. Financial Performance

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Outlook 2025: Mapping Growth, Innovation, and Regional Shifts

Global Vutrisiran Market Trends: Regional Breakdowns and Strategic Insights

Vyndaqel Outlook 2034: Key Drivers, Trends, and Market Frontiers

Functional Dyspepsia DrugMarket Overview 2025–2034: CAGR Trends, Long-Term Growth Paths, and Business Implications

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Alpha Mannosidosis Market 2022 - By Therapy Type (Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Peripheral Blood Stem Cell Transplantation (PBSCT)), By Indication (Type I, Type II, Type III), By End Use...

Bone Marrow Transplantation Global Market Report 2025 – By Type (Autologous Bone Marrow Transplant, Allogenic Bone Marrow Transplant), By Indication (Hodgkin Lymphoma, Acute Leukemia, Multiple Myelomas, Solid Tumors, Non...

Multiple Myeloma Drugs Global Market Report 2025 – By Drug Type (Immunomodulatory Drugs, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Monoclonal Antibody Drugs, Steroids, Other Drug Types), By Therapy (Targeted...

Multiple Myeloma Global Market Report 2025 – By Treatment (Medications, Radiation Therapy, Stem Cell Transplant, Other Treatments), By Diagnosis (Blood Tests, Bone Marrow Biopsy, Urine Tests, Imaging Tests), By Disease T...

Neurodegenerative Disorder Therapeutics Global Market Report 2025 – By Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types), By Drug Type (N- methyl- ...

Antisense & RNAi Therapeutics Global Market Report 2025 – By Technology (RNA Interference, Antisense RNA), By Route of Administration (Intravenous Injections, Intra-dermal Injections, Other Delivery Methods), By Indicati...

Human Microbiome Therapeutics Market - By Disease (Infectious Diseases, Gastrointestinal Disorders, Metabolic Disorders, Cancers), By Sequencing Technology Type (Targeted Gene, RNA, Whole-Genome Shotgun (WGS)) And By Reg...

Frequently Asked Questions

What is the definition of the Sarclisa market?

How will the Sarclisa market drivers and restraints affect the market dynamics? What forces will shape the Sarclisa industry going forward?

The Sarclisa market major growth driver - Rising Cancer Prevalence Drives Growth In The Sarclisa Market. For further insights on the Sarclisa market, request a sample here

What is the forecast market size or the forecast market value of the Sarclisa market?

The Sarclisa market size has grown strongly in recent years. The sarclisa market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to significant investments in oncology research, improvements in healthcare infrastructure, increasing aging population, government funding and reimbursement policies for cancer treatments, and expanding clinical trial programs. The sarclisa market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to growth of personalized medicine, shift toward immunotherapies, increasing prevalence of autoimmune diseases, growing focus on long-term remission, and awareness of hematological malignancies. Major trends in the forecast period include shift towards more targeted therapies, launch of biosimilars, advancements in molecular diagnostics, technological advancements in cancer diagnosis, and innovation in targeted cancer therapies. For further insights on the Sarclisa market, request a sample here

How is the Sarclisa market segmented?

The sarclisa market covered in this report is segmented –
1) By Formulation: Injectable Solution; Lyophilized Powder for Injection
2) By Clinical Indication: Relapsed Or Refractory Multiple Myeloma; Newly Diagnosed Multiple Myeloma
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies For further insights on the Sarclisa market, request a sample here

Which region has the largest share of the Sarclisa market? What are the other regions covered in the report?

Who are the major players in the Sarclisa market?

Major companies operating in the sarclisa market are Sanofi S.A. . For further insights on the Sarclisa market, request a sample here.

What are the key trends in the Sarclisa market?

Major trends in the Sarclisa market include Regulatory Approvals Drive Growth In The Sarclisa Market For Newly Diagnosed Multiple Myeloma. For further insights on the Sarclisa market, request a sample here.